GINKGO BIOWORKS HOLDINGS INC
DNANYSETrading Snapshot
- Day Range
- $324.86 – $332.31
- 52-Week Range
- $5.37 – $17.58
- Volume
- $5.31B
- Avg Volume
- $5.00B
- Shares Outstanding
- 65.3M
- Next Earnings
- Dec 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $170M
- Last Q Revenue
- $20M
- P/E Ratio
- -2.4
- P/S Ratio
- 7.0x
- EPS (TTM)
- $-4.68
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +6.9%
Why Investors Own DNA
- ✓High-growth profile — revenue up +39.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GINKGO BIOWORKS HOLDINGS INC
DNA
StockOtter · stockotter.spaceAbout GINKGO BIOWORKS HOLDINGS INC
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
GINKGO BIOWORKS HOLDINGS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift DNA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
GINKGO BIOWORKS HOLDINGS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.